BioSpace News Archive

Despite recent investment and breakthroughs for rare diseases such as Friedreich’s ataxia and progeria, experts say helping patients with rare diseases will require cross-sector support.

Congressional legislation seeks to “equalize” the negotiating period between biologics and small molecules under the Inflation Reduction Act’s Drug Price Negotiation Program.

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia.

Ocugen, Inc. announced that the Clinical Showcase webcast from the February 21, 2024 live event is now available in the Events & Presentations section of the Ocugen website.

Heron Therapeutics, Inc. today announced that the company will host a conference call and live webcast on Tuesday, March 12, 2024, at 4:30 p.m. ET to report fourth quarter and full year 2023 financial results and discuss recent business highlights.

KORE, a global leader in Internet of Things (“IoT”) Solutions, and Medical Guardian, a leading provider of personal emergency response systems (PERS), jointly announce their groundbreaking collaboration on the first-ever medical alert device utilizing eSIM technology.

RRD International has announced today that it launched its new brand RRD Biopharma Development reflecting its unique offering of delivering strategy-driven product development services to biopharmaceutical companies and investors.

Edgewise Therapeutics, Inc. today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association Clinical and Scientific Conference.

Thermo Fisher Scientific to Present at TD Cowen 44th Annual Health Care Conference on March 6, 2024.

Silence Therapeutics plc today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024.